TranspireBio Completed Phase 1 Inhaler Study
The study validates a new soft mist delivery platform intended to improve how patients receive therapeutic medications.
Updated on Oct. 6, 2026 in Asthma
Live Poll
Do you believe advancements in medical delivery devices will improve patient access to treatments?
TranspireBio announced the completion of a Phase 1 pharmacokinetic study evaluating its Springboard Soft Mist Inhaler. The device met all primary and secondary safety and tolerability endpoints for the drug delivery platform.
Why it matters
Successful completion of this trial enables the company to advance multiple clinical programs using its proprietary inhalation technology. This progress marks a key step in developing new delivery options for patients managing chronic respiratory conditions.
In a Phase 1 pharmacokinetic clinical study, the Springboard Soft Mist Inhaler platform met all primary and secondary endpoints. Researchers observed low within-subject variability in the delivery profile, confirming the safety and tolerability of the proprietary system.
The players
TranspireBio
A Florida-based biotechnology company focused on developing inhalation drug delivery platforms and respiratory therapies.
The details
The Springboard platform uses proprietary technology to create a soft mist, which is designed to optimize the delivery of medicine into the lungs. By standardizing the pharmacokinetic profile, this delivery method aims to provide consistent dosing for patients. The company is now using the data from this trial to support the continued development of its broader respiratory medicine portfolio.
Timeline
October 6, 2026: TranspireBio announced the completion of the Phase 1 study.
2028: A new manufacturing site is planned for Pembroke Pines, Florida.
Health Landscape
This development follows a long history of refinement in pulmonary drug delivery technology, moving away from legacy pressurized metered-dose inhalers. The Springboard platform represents an effort to improve medication consistency compared to current aerosol-based standards.
While this device is currently in clinical development, advancements in inhaler technology may eventually offer more reliable symptom control for those with chronic airway diseases. These developments are worth discussing with your doctor to understand how delivery systems impact your asthma care plan.
The takeaway
This Phase 1 study indicates that the Springboard delivery technology is safe and performs with low variability in trial settings. Patients should continue to monitor updates regarding new medical devices with their pulmonologist as clinical development progresses.
Further reading
For more information on managing respiratory health, visit our Asthma section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe advancements in medical delivery devices will improve patient access to treatments?
